These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38085501)

  • 1. Sarcopenia is a risk factor for post-transjugular intrahepatic portosystemic shunt hepatic encephalopathy and mortality: A systematic review and meta-analysis.
    Ahmed Z; Badal J; Gangwani MK; Nawaz A; Badal B; Arif SF; Farooq U; Kamal F; Javaid T; Aziz M; Lee-Smith W; Mahmood A; Merza N; Kobeissy A; Nawras A; Hassan M
    Indian J Gastroenterol; 2024 Aug; 43(4):748-759. PubMed ID: 38085501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis.
    Brand M; Prodehl L; Ede CJ
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001023. PubMed ID: 30378107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.
    Luo SH; Chu JG; Huang H; Zhao GR; Yao KC
    World J Gastroenterol; 2019 Mar; 25(9):1088-1099. PubMed ID: 30862997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
    Dissegna D; Sponza M; Falleti E; Fabris C; Vit A; Angeli P; Piano S; Cussigh A; Cmet S; Toniutto P
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):626-632. PubMed ID: 30550458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of Model for End-Stage Liver Disease (MELD) and Sarcopenia predicts mortality after transjugular intrahepatic portosystemic shunt (TIPS).
    Delgado MG; Mertineit N; Bosch J; Baumgartner I; Berzigotti A
    Dig Liver Dis; 2024 Sep; 56(9):1544-1550. PubMed ID: 38555198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nutritional status in hepatic encephalopathy and transjugular intrahepatic portosystemic shunt - TIPS, and strategies to improve the outcomes.
    Berenguer M
    Acta Gastroenterol Belg; 2023; 86(2):318-322. PubMed ID: 37428165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.
    Teng D; Zuo H; Liu L; Dong J; Ding L
    Virol J; 2018 Oct; 15(1):151. PubMed ID: 30285813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy: Sarcopenia Adds Insult to Injury.
    Bhatia Kapoor P; Benjamin J; Tripathi H; Patidar Y; Maiwall R; Kumar G; Joshi YK; Sarin SK
    Turk J Gastroenterol; 2023 Apr; 34(4):406-412. PubMed ID: 36620928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects and complications of the transjugular intrahepatic portosystemic shunt: a single-centre experience.
    Kraglund F; Jepsen P; Amanavicius N; Aagaard NK
    Scand J Gastroenterol; 2019 Jul; 54(7):899-904. PubMed ID: 31203699
    [No Abstract]   [Full Text] [Related]  

  • 10. Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt.
    Yin L; Chu SL; Lv WF; Zhou CZ; Liu KC; Zhu YJ; Zhang WY; Wang CX; Zhang YH; Lu D; Cheng DL
    World J Gastroenterol; 2023 May; 29(18):2875-2887. PubMed ID: 37274064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.
    Yao J; Zuo L; An G; Yue Z; Zhao H; Wang L; Liu F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):301-7. PubMed ID: 26405702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.
    Nardelli S; Riggio O; Marra F; Gioia S; Saltini D; Bellafante D; Adotti V; Guasconi T; Ridola L; Rosi M; Caporali C; Fanelli F; Roccarina D; Bianchini M; Indulti F; Spagnoli A; Merli M; Vizzutti F; Schepis F
    J Hepatol; 2024 Apr; 80(4):596-602. PubMed ID: 38097113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between sarcopenia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: a systematic review and meta-analysis.
    Li Y; Guo Y; Wang X; Gao L
    Abdom Radiol (NY); 2024 Feb; 49(2):575-585. PubMed ID: 37980601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy.
    Deng D; Liao MS; Qin JP; Li XA
    Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):232-6. PubMed ID: 16698582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcopenia is an independent risk factor for short-term mortality in patients undergoing transjugular intrahepatic portosystemic shunt.
    Stoffel E; Hwang SY; Qian X; Geller B; Morelli G; Zhang W
    Eur J Gastroenterol Hepatol; 2024 Aug; 36(8):1010-1015. PubMed ID: 38808872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of portosystemic gradient during transjugular intrahepatic portosystemic shunt achieves good outcome and reduces complications.
    Luo SH; Zhou MM; Cai MJ; Han SL; Zhang XQ; Chu JG
    World J Gastroenterol; 2023 Apr; 29(15):2336-2348. PubMed ID: 37124886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
    Wang Z; Wu YF; Yue ZD; Zhao HW; Wang L; Fan ZH; Zhang Y; Liu FQ
    World J Gastroenterol; 2021 Feb; 27(5):416-427. PubMed ID: 33584073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
    Colombato L
    J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian network-based survival prediction model for patients having undergone post-transjugular intrahepatic portosystemic shunt for portal hypertension.
    Chen R; Luo L; Zhang YZ; Liu Z; Liu AL; Zhang YW
    World J Gastroenterol; 2024 Apr; 30(13):1859-1870. PubMed ID: 38659484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of post-tips hepatic encephalopathy: The search of the ideal candidate.
    Nardelli S; Bellafante D; Ridola L; Faccioli J; Riggio O; Gioia S
    Metab Brain Dis; 2023 Jun; 38(5):1729-1736. PubMed ID: 36445629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.